Desai, Akshay S.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 7,140

Angiotensin-neprilysin inhibition versus enalapril in heart failure

McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 6,957

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 2,884

Spironolactone for heart failure with preserved ejection fraction

Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 2,809

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 2,430

Strategies for Multivessel Revascularization in Patients with Diabetes

Farkouh, M. E., Domanski, M., Sleeper, L. A., Siami, F. S., Dangas, G., Mack, M., Yang, M., Cohen, D. J., Rosenberg, Y., Solomon, S. D., et al. (2012) · New England Journal of Medicine

Coronary Interventions and DiagnosticsCardiac Imaging and Diagnostics

Cited by 1,922

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine

Renin-Angiotensin System StudiesChronic Kidney Disease and Diabetes

Cited by 1,319

SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 996

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 893

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation

Statistical Methods in Clinical TrialsPharmacovigilance and Adverse Drug Reactions

Cited by 750

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Packer, M., McMurray, J. J. V., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2015) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 673

Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 639

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus

Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 557

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Solomon, S. D., Vaduganathan, M., L. Claggett, B., Packer, M., Zile, M., Swedberg, K., Rouleau, J., A. Pfeffer, M., Desai, A., H. Lund, L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 551

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 531

Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial

Greenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Desai, A. S., Barnard, D., Bouchard, A., Jaski, B., Lyon, A. R., et al. (2016) · The Lancet

Virus-based gene therapy researchHeart Failure Treatment and Management

Cited by 525

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 359

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF

Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 307

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 217

Incidence and Predictors of Hyperkalemia in Patients With Heart Failure

Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., et al. (2007) · Journal of the American College of Cardiology

Potassium and Related DisordersHeart Failure Treatment and Management

Cited by 170

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction

Gilstrap, L. G., Fonarow, G. C., Desai, A. S., Liang, L., Matsouaka, R., DeVore, A. D., Smith, E. E., Heidenreich, P., Hernandez, A. F., Yancy, C. W., et al. (2017) · Journal of the American Heart Association

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 169

Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction

Bello, N. A., Claggett, B., Desai, A. S., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., & Solomon, S. D. (2014) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 147

Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 145

Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

Lewis, E. F., Kim, H.-Y., Claggett, B., Spertus, J., Heitner, J. F., Assmann, S. F., Kenwood, C. T., Solomon, S. D., Desai, A. S., Fang, J. C., et al. (2016) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 114